AI Article Synopsis
- Transplantation is the key treatment for severe organ failures, but immune rejection often limits its success; this study explores a new approach using exosomes from melanoma cells to combat this issue.
- The research shows that these tumor-derived exosomes (B16-Exo) significantly reduce immune rejection in mouse corneal transplants, improving survival and reducing inflammation.
- Analysis reveals that B16-Exo influences important proteins, particularly JAK2 in the JAK-STAT pathway, which enhances the activity of immune-suppressing cells and reduces T cell activity, highlighting the potential of exosomes for improving transplant outcomes.
Article Abstract
Transplantation remains the definitive treatment for end-stage organ failures, but its efficacy is frequently compromised by immune rejection. This study introduces a novel strategy by utilizing tumor-derived exosomes from B16-F10 melanoma cells (B16-Exo), diverging from the conventional use of immune cell-derived exosomes, to alleviate post-transplantation immune rejection. Utilizing murine corneal transplantation as a model, it is demonstrated that B16-Exo significantly reduces immune rejection, evidenced by decreased corneal opacity, neovascularization, and immune dysregulation, while enhancing postoperative survival. Proteomic analyses reveal differential expression of pivotal proteins in B16-Exo, notably the JAK2 protein within the JAK-STAT signaling pathway, which has been mechanistically demonstrated to amplify the activity of myeloid-derived suppressor cells (MDSCs) and inhibit T cell proliferation. These findings demonstrate the significant immunomodulatory effect of B16-Exo in transplant immunology, supporting the continued exploration of tumor-derived exosomes as a platform to uncover novel immunosuppressive mechanisms in transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/advs.202409207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gbp2 driving macrophages dynamics in murine heart transplant.
Tissue Cell
December 2024
Department of General Surgery, Tianjin Medical University General Hospital, No. 154, Anshan Road, Heping District, Tianjin 300052, China; Tianjin Key Laboratory of Precise Vascular Reconstruction and Organ Function Repair, No. 154, Anshan Road, Heping District, Tianjin 300052, China. Electronic address:
Background And Objective: Organ transplantation is a vital treatment for patients with end-stage organ diseases, and macrophages play a key role in the rejection process. This study seeks to pinpoint key genes responsible for the dynamic changes in macrophages during rejection and to evaluate their impact on macrophage polarization through bioinformatics analysis.
Methods: We selected single-cell sequencing data of mouse heart transplant models from Genome Sequence Archive to construct a dynamic landscape of immune cells during acute rejection.
Alemtuzumab Associated With Higher Mortality Than Basiliximab in Older Kidney Transplant Recipients.
J Surg Res
December 2024
Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Introduction: Kidney transplantation (KT) in older age is increasingly common as more elderly patients live with end-stage renal disease. Immunosuppression (IS) after KT confers additional risk in aging patients with weakened immune systems. We hypothesized that 1-year mortality among KT recipients aged 70 y and older would be higher in those receiving induction IS with alemtuzumab lymphocyte depletion versus basiliximab interleukin-2 inhibition.
View Article and Find Full Text PDFRandomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression.
Am J Transplant
December 2024
Institute of Liver Studies, King's College London University and King's College Hospital, London, United Kingdom. Electronic address:
The maintenance of stable allograft status in the absence of immunosuppression, known as operational tolerance, can be achieved in a small proportion of liver transplant recipients, but we lack reliable tools to predict its spontaneous development. We conducted a prospective, multi-center, biomarker-strategy design, immunosuppression withdrawal clinical trial to determine the utility of a predictive biomarker of operational tolerance. The biomarker test, originally identified in a patient cohort with high operational tolerance prevalence, consisted of a 5-gene transcriptional signature measured in liver tissue collected before initiating immunosuppression weaning.
View Article and Find Full Text PDFT Cell Development and Responses in Human Immune System Mice.
Annu Rev Immunol
December 2024
2Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, NY, USA;
Human Immune System (HIS) mice constructed with mature human immune cells or with human hematopoietic stem cells and thymic tissue have provided an important tool for human immunological research. In this article, we first review the different types of HIS mice based on human tissues transplanted and sources of the tissues. We then focus on knowledge of human T cell development and responses obtained using HIS mouse models.
View Article and Find Full Text PDFTiming of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
Vaccine
December 2024
Univ. Grenoble Alpes, Groupe de Recherche en Infectiologie Clinique, CIC-1406, INSERM, Infectious diseases department, Grenoble Alpes University Hospital, Grenoble, France. Electronic address:
Objectives: SARS-CoV-2 mRNA vaccine reactogenicity has raised concerns regarding the risk of rejection in solid organ transplant recipients. We explored whether SOT recipients diagnosed with acute rejection had previously received a vaccine injection within a timeframe consistent with a causal link.
Methods: We identified all SOT recipients with a diagnosis of acute rejection from 2020 to 2022 and who had previously received a SARS-CoV-2 vaccination, and analysed whether the delay between vaccination and rejection was constant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!